Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — ITUS — Shareholder Meeting (September 2018)
15 slides from Anixa Biosciences's shareholder meeting presentation, Sep 27, 2018
Slide 1: ITUS Corporation Annual Shareholder Meeting
CORPORATION ITUS Corporation Presentation: Annual Shareholder Meeting September 27, 2018 NASDAQ:ITUS Amit Kumar, Ph.D. (Soon to Be Anixa Biosciences, Inc.)
Slide 2: Forward-Looking Statements
ITUS CORPORATION Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are not statements of historical facts, but rather reflect ITUS Cor
Slide 3: Outline
ITUS CORPORATION Outline ¢ Background and Reflection on the Last Year ¢ Plans and Goals for remainder of 2018 and 2019 ¢ Update on both programs ¢ Update on CAR-T program ¢ Update on Or Ghali “Q&A
Slide 4: Background
ITUS CORPORATION Background * Management Change in July 2017 ¢ Team with Amit Kumar, Ph.D. as CEO for roughly 14 months ¢ John Roop, SVP Engineering * Mike Catelani, COO, CFO * Tony Campisi, VP Engineering * George Dominguez, Ph.D., Senior Scientist * Alex Polo, Scientist ¢ Chereen Abushaaban, Offic
Slide 5: Leverage-Able Business Model
ITUS CORPORATION Leverage-Able Business Model Corporate f Commercialization Partnership Research Development Additional Data Regulatory Strategy Develop IP Invent/License Regulatory Technology Testing and License Fee Approval Milestones Manufacturing R&D Support Marketing, Sales, Revenue Distributio
Slide 6: Major Accomplishments
ITUS CORPORATION Major Accomplishments ¢ Licensed CAR-T Technology from The Wistar Institute ¢ Established Cooperative R&D Agreement with Moffitt Cancer Center ¢ Accelerated Development Timeline for CAR-T Program ¢ Requested Meeting with the FDA, Over a Year Ahead of Schedule ¢ Presented Cchek Data
Slide 7: Stock Performance since July 2017
ITUS CORPORATION Stock Performance since July 2017 ITUS ¢ Prefer not to predict stock price 5 * Our primary goal is shareholder value creation ¢ We have chosen to create ‘ shareholder value by engaging in the war against cancer ¢ Value Creation in Biotech can be 2 Dramatic but Volatile
Slide 8: Goals for Calendar Q4-2018 and 2019 - CAR-T
ITUS CORPORATION Goals for Calendar Q4-2018 and 2019- CAR-T * Pre-IND (Investigational New Drug) Meeting with FDA * Meeting Scheduled for October 16, 2018 ¢ Written Communication Shortly After ¢ File IND Application * Begin First in Human Clinical Trial (as early as calendar Q1/Q2-2019 time frame) *
Slide 9: Goals for Calendar Q4-2018 and 2019 - Cchek
ITUS CORPORATION Goals for Calendar Q4-2018 and 2019-€ ccner. ¢ File Pre-IDE (Investigational Device Exemption) with FDA * Meet with FDA-OIVD- Calendar Q4-2018 or Q1-2019 * Determine Commercialization Strategy * Continue Presenting Data at Scientific Conferences * Publish Data in Peer-Reviewed Publi
Slide 10: Corporate Goals
ITUS CORPORATION ITUS Corporate Goals ¢ Change Name to Anixa BioSciences, Ticker to ANIX- Next Week * No action needed by shareholders ¢ Financial websites will update ticker within a day or two ¢ Achieve analyst coverage * Create more visibility with Institutional Investors
Slide 11: Stockholder Comments and Questions
ITUS CORPORATION Stockholder Comments and Questions ¢ We always return stockholder calls ¢ May take time as we are a small team and busy ¢ Prefer calls rather than emails even though they take more time ¢ Please be cognizant of our time * Sometime in the near future, we hope to begin quarterly confe
Slide 12: Update on Both Programs
ITUS CORPORATION Update on Both Programs Two specific initiatives utilizing an understanding and control of the dynamic interaction between tumors and the immune system * Liquid Biopsy--& cenev ¢ CAR-T- Chimeric Antigen ¢ Early Cancer Diagnostic Receptor T-cells ¢ Therapy for Ovarian Cancer ¢ Early
Slide 13: Update - CAR-T
Update- CAR-T ¢ Ahead of schedule * October 16, 2018 FDA Meeting ¢ Minutes from FDA in 30-60 days ¢ Assuming no further animal studies are needed: ¢ We expect to file our IND in Calendar Q4-2018 or early 2019 ¢ We expect FDA approval to move to clinical trials * Begin Human Testing in Calendar Q1/Q2
Slide 14: Update - Cchek
ITUS CORPORATION Update- € cer ¢ Artificial Intelligence (Al) better than scientist or physician ¢ May work for all cancers * To date, identified in 20 different types ¢ Majority: Breast and Prostate * Other: Lung, Colon, Pancreatic, Melanoma, Ovarian, Liver, Bladder, Cervical, Endometrial, Uterine,
Slide 15: Questions
CORPORATION Questions